Title: Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study

Authors: Xiaomeng Zhang¹, Xue Li¹, Ziwen Sun⁵, Yazhou He¹, Wei Xu¹, Harry Campbell¹, Malcolm G Dunlop², Maria Timofeeva^{2,3*}, Evropi Theodoratou^{1,4*}

¹Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom

²Colon Cancer Genetics Group, Cancer Research UK Edinburgh Centre and Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, United Kingdom

³DIAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark, Odense, Denmark

⁴Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, United Kingdom

⁵OPENspace Research Centre, Edinburgh School of Architecture and Landscape Architecture, The University of Edinburgh, Edinburgh, United Kingdom

*: Corresponding authors

Evropi Theodoratou, Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh,

United Kingdom, e.theodoratou@ed.ac.uk, (+44) 0131 650 3210

Maria Timofeeva, Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom, <u>maria.timofeeva@igmm.ed.ac.uk</u>, (+44) 131 651 8687

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Physical activity (PA) is known to be a protective lifestyle factor against several non-communicable diseases while its impact on infectious diseases, including Coronavirus Disease 2019 (COVID-19) is not as clear. We performed univariate and multivariate logistic regression to identify associations between body mass index (BMI) and both objectively and subjectively measured PA collected prospectively and COVID-19 related outcomes (Overall COVID-19, inpatient COVID-19, outpatient COVID-19, and COVID-19 death) in the UK Biobank (UKBB) cohort. Subsequently, we tested causality by using two-sample Mendelian randomisation (MR) analysis. In the multivariable model, the increased acceleration vector magnitude PA (AMPA) was associated with a decreased probability of overall and outpatient COVID-19. No association was found between self-reported moderate-to-vigorous PA (MVPA) or BMI and COVID-19 related outcomes. Although no causal association was found by MR analyses, this may be due to limited power and we conclude policies to encourage and facilitate exercise at a population level during the pandemic should be considered.

1 Introduction

- 2 Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2
- 3 (SARS-CoV-2) was declared a pandemic on Mar 11th, 2020 by the World Health Organisation (WHO).
- 4 By July 29th, 2020, a total of 16,558,289 patients had been diagnosed, with 656,093 confirmed
- 5 deaths globally.¹ National responses to the pandemic including a range of non-pharmacological
- 6 interventions [NPIs], have been adopted by countries at nation-wide, state-wide, or city-wide levels.
- 7 The restrictions imposed by governments during the outbreak have had a substantial impact on
- 8 patterns of physical activity (PA) within populations. For example, an online survey conducted in
- 9 Canada indicated that 40.5% of physically inactive individuals became less active and 33% became
- 10 more active; 22.4% of physically active individuals became less active and 40.3% became more active
- 11 during lockdown time.²
- 12 PA is known to be a protective lifestyle factor for a number of non-communicable diseases (e.g.
- 13 cancer and cardiovascular disease) and aging processes (e.g. immunosenescence).³⁻⁵ However,
- 14 evidence of the role of PA on respiratory viral infections remains weak, especially for highly
- 15 contagious viruses like SARS-CoV-2. Since doing exercise could compromise social distancing
- 16 measures and increase opportunities for contracting the virus (probably indoors more than
- 17 outdoors), it is unclear whether being physically active is a beneficial lifestyle factor for respiratory
- 18 viral infections. Viral pathogenesis has been reported to be greater in obese or overweight
- 19 individuals⁶ and obesity has been suggested as a mediator for PA effects. In this study, we analysed
- 20 whether PA and body mass index (BMI) influence the risk of COVID-19 and then investigated any
- 21 causal associations between PA, BMI, and COVID-19 by applying two-sample Mendelian
- 22 Randomisation (MR) analysis.

23 Results

24 The characteristics of participants in the four outcome groups (overall COVID-19, inpatient COVID-25 19, outpatient COVID-19, and COVID-19 death), and the included controls were described in Table 1. 26 Patients who died from COVID-19 had the highest average age (74.66) while outpatients had the 27 lowest average age (65.97). The proportion of males was the highest for the COVID-19 death group (63.91%) and the lowest for the control group (45.57%). Participants in the inpatient COVID-19 group 28 29 had the longest MVPA time while participants in the outpatient group had the shortest. For AMPA, participants in the control group have the longest AMPA time while patients who died from COVID-30 31 19 have the shortest. The results of univariate and multivariate logistic regression of two types of PA 32 on the four outcomes are presented in Table 2. The results of univariate and multivariate logistic

regression of BMI on the four outcomes are presented in Table S1. The results of two-sample MR
 analyses are presented in Figure 1 and Table S2.

3 A total of 500,758 participants (96,460 participants have AMPA data) from the UKBB were included 4 as controls of the observational analyses. For the COVID-19 test result records, 1,596 patients were 5 COVID-19 positive, of these, 1,020 were inpatients and 576 were outpatients. In addition, 399 6 participants had died of COVID-19 (with 376 deaths having COVID-19 as primary cause of death), in 7 which 249 had SARS-CoV-2 positive results. In the multivariate logistic regression models, AMPA was associated with decreased risk of contracting COVID-19 and attending as an outpatient with a 8 9 COVID-19 related health concern. The odds ratio (OR) and 95% confidence interval (95% CI) per SD 10 increase of AMPA were 0.80 (0.69, 0.93) and 0.74 (0.58, 0.95) respectively after adjusting for age, 11 gender, and measures of body fatness (Table 2). Further adjusting smoking status, the OR (95%CI) 12 was 0.81 (0.69, 0.96) for association between AMPA on overall COVID-19. In the univariate model, 13 AMPA related to a decreased risk of COVID-19 death while the association disappeared after 14 adjusting for the other covariates. On the contrary, MVPA was not associated with any of the COVID-19 outcomes (Table 2). The observational analysis did not indicate an association between BMI and 15 16 COVID-19 outcomes (Table S1). The sensitivity analyses reported similar results with the main 17 analyses (Tables S3 & S4).

A total of 342,678 participants with genotype data were included in the MR analysis after sample quality control. Of these, 9,494 participants had COVID-19 test results. The effect estimates of the instrumental variables on COVID-19 are listed in Table S5. AMPA detected to be associated with a lower risk of inpatient COVID-19 by the MR-Egger method, however, the intercept of MR-Egger also indicated the existence of pleiotropic effects. Significant heterogeneity has not been detected by Q statistics (Figure 1 and Supplementary Table 2). MVPA and BMI were not found to be causally linked to COVID-19 outcomes in this cohort.

Table 1 Characteristics of UK Biobank participants											
	Overall COVID-19	Inpatient COVID-19	Outpatient COVID-19	COVID-19 deaths	Controls	Controls*					
	cases	cases	cases	N(0/)/Moon (SD)							
	N (%)/Mean (SD)	N (%)/Mean (SD)	N (%)/Mean (SD)	N (%)/ Near (SD)	N (%)/ Near (SD)	N (%)/ Nedit (SD)					
All participants	1746 (0.35%)	1020 (0.20%)	576 (0.11%)	399 (0.07%)	500758 (99.65%)	415596 (99.65%)					
Age	68.76 (9.18)	69.40 (8.86)	65.97 (9.41)	74.66 (5.98)	68.46 (8.11)	68.14 (8.08)					
Sex	Male (52.92%)	Male (55.88%)	Male (45.83%)	Male (63.91%)	Male (45.57%)	Male (44.63%)					
MVPA (MET-minutes/week)	990.40 (1310.75)	1039.00 (1356.07)	898.7 (1236.67)	1017.00 (1057.92)	973.80 (1269.00)	974.60 (1268.05)					
AMPA (milli-gravities)	26.72 (8.57) (n=215)	26.59 (8.85) (n=122)	27.38 (8.08) (n=79)	24.13 (8.10) (n=36)	28.00 (8.24) (n=96460)	28.12 (8.19) (n=83748)					
BMI (kg/m ²)	27.53 (4.88)	27.47 (4.81)	27.66 (5.01)	27.59 (4.68)	27.41 (4.79)	27.41 (4.80)					
Waist circumference (cm)	90.76 (14.01)	91.25 (14.51)	90.15 (13.19)	90.66 (14.56)	90.32 (13.48)	90.30 (13.47)					
Hip circumference (cm)	103.10 (9.45)	102.90 (9.84)	103.40 (8.77)	103.20 (9.33)	103.4 (9.25)	103.4 (9.24)					
Currently Smoking	153 (8.76%)	92 (9.02%)	47 (8.16%)	34 (8.52%)	38198 (7.63%)	31573 (7.60%)					
Exposure to smoking at home (hour/week)	0.47 (4.07)	0.48 (4.49)	0.53 (3.77)	0.42 (4.01)	0.49 (4.44)	0.49 (4.46)					
Exposure to smoking out of home (hour/week)	0.35 (2.26)	0.37 (2.31)	0.37 (2.41)	0.40 (3.36)	0.37 (2.44)	0.37 (2.45)					
COVID-19: Coronavirus Disease 2019, N: number, SD: standard deviation, BMI: body mass index, MVPA: self-reported moderate-to-vigorous physical activity,											
AMPA: acceleration vector magnitude physical activity, *: control group that excludes participants who are not in England, who died before 01/01/2020, and who											
		have tested n	egative for SARS-CoV-2.								

				Tal	ble 2 Association analys	is between	types physical ac	tivity and four	r COVID-19 related	outcomes						
		Overall CO	VID-19			npatients (COVID-19			Outpatient	s COVID-19			COVID-1	0-19 death	
	MVPA (Subjective)	y measured)	AMPA (Objecti measured)	vely	MVPA (Subject measured)	ively)	AMPA (Obje measure	ctively ed)	MVPA (Subje measure	ctively d)	AMPA (Objec measure	tively d)	MVPA (Subje measure	ctively d)	AMPA (Objec measure	ctively d)
	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р
Physical activity	1.01 (0.97, 1.06)	0.584	0.84 (0.73, 0.98)	0.021	1.05 (0.99, 1.11)	0.104	0.83 (0.68, 1.00)	0.056	0.94 (0.86, 1.02)	0.156	0.92 (0.74, 1.16)	0.495	1.03 (0.94, 1.14)	0.493	0.56 (0.38, 0.83)	0.004
Physical activity	1.01 (0.97, 1.06)	0.591	0.80 (0.69, 0.92)	0.003	1.05 (0.99, 1.11)	0.105	0.84 (0.69, 1.02)	0.086	0.96 (0.86, 1.02)	0.152	0.74 (0.58 <i>,</i> 0.95)	0.017	1.03 (0.94, 1.14)	0.485	0.79 (0.53, 1.17)	0.239
Age	1.00 (1.00 1.01)	0.155	0.97 (0.95, 0.99)	3.09E- 04	1.01 (1.01, 1.02)	3.70E- 04	1.00 (0.97, 1.02)	0.754	0.96 (0.95, 0.97)	2.81E- 13	0.90 (0.88 <i>,</i> 0.93)	1.46E- 11	1.13 (1.11, 1.15)	3.47E- 45	1.18 (1.10, 1.26)	2.42E- 06
Sex	1.34 (1.22, 1.47)	1.09E-09	1.36 (1.04, 1.78)	0.024	1.50 (1.33, 1.70)	1.04E- 10	1.83 (1.27, 2.62)	0.001	1.02 (0.87, 1.21)	0.784	0.84 (0.54, 1.33)	0.468	2.00 (1.63, 2.45)	3.41E- 11	1.84 (0.93, 3.65)	0.08
Physical activity	1.02 (0.97, 1.06)	0.504	0.80 (0.69, 0.93)	0.003	1.05 (0.99, 1.11)	0.108	0.85 (0.70, 1.03)	0.096	0.95 (0.87, 1.03)	0.233	0.74 (0.58 <i>,</i> 0.95)	0.019	1.04 (0.94, 1.14)	0.449	0.78 (0.52, 1.17)	0.235
Age	1.00 (1.00, 1.01)	0.156	0.97 (0.95, 0.99)	2.66E- 04	1.01 (1.01, 1.02)	4.20E- 04	1.00 (0.97, 1.02)	0.756	0.96 (0.95, 0.97)	2.51E- 13	0.90 (0.87, 0.93)	7.48E- 12	1.13 (1.11, 1.15)	3.30E- 45	1.18 (1.10, 1.26)	2.45E- 06
Sex	1.33 (1.21, 1.47)	2.29E-09	1.33 (1.02, 1.75)	0.037	1.50 (1.32, 1.70)	1.70E- 10	1.80 (1.25, 2.58)	0.002	1.01 (0.86, 1.19)	0.882	0.80 (0.50, 1.28)	0.351	1.98 (1.61, 2.43)	6.89E- 11	1.84 (0.93 <i>,</i> 3.65)	0.082
Waist circumference	1.00 (1.00, 1.01)	0.231	1.00 (0.99, 1.01)	0.557	1.00 (1.00, 1.01)	0.05	1.01 (1.00, 1.03)	0.05	1.00 (0.99, 1.01)	0.789	0.99 (0.97 <i>,</i> 1.00)	0.097	1.00 (0.99, 1.01)	0.78	1.00 (0.98, 1.03)	0.891
Hip circumference	1.00 (0.99, 1.00)	0.166	1.00 (0.99, 1.02)	0.871	0.99 (0.99, 1.00)	0.101	1.01 (0.98, 1.02)	0.87	1.00 (0.99, 1.01)	0.993	1.00 (0.97, 1.02)	0.884	1.00 (0.99, 1.01)	0.652	0.99 (0.95 <i>,</i> 1.03)	0.644
BMI	1.01 (1.00, 1.01)	0.315	1.01 (0.98, 1.04)	0.52	1.00 (0.99, 1.02)	0.67	1.00 (0.96, 1.04)	0.981	1.01 (0.99, 1.03)	0.264	1.03 (0.98 <i>,</i> 1.07)	0.21	1.01 (0.99, 1.03)	0.505	0.99 (0.92 <i>,</i> 1.06)	0.761
Physical activity	1.01 (0.95, 1.06)	0.876	0.82 (0.69, 0.96)	0.012	1.05 (0.98, 1.11)	0.166	0.85 (0.69, 1.05)	0.129	0.93 (0.85, 1.03)	0.155	0.79 (0.61, 1.03)	0.078	1.00 (0.90, 1.11)	0.966	0.74 (0.48, 1.14)	0.172
Age	1.00 (1.00, 1.00)	0.144	0.98 (0.96, 0.99)	0.01	1.02 (1.01, 1.02)	4.31E- 04	1.01 (0.98, 1.03)	0.658	0.96 (0.95, 0.97)	2.36E- 12	0.90 (0.87, 0.93)	8.53E- 10	1.13 (1.11, 1.16)	4.46E- 40	1.21 (1.12, 1.31)	1.30E- 06
Sex	1.36 (1.22, 1.50)	5.93E-09	1.41 (1.05, 1.88)	0.021	1.50 (1.31, 1.72)	2.98E- 09	1.94 (1.31, 2.88)	9.22E- 04	1.08 (0.91, 1.30)	0.373	0.84 (0.51, 1.39)	0.505	1.90 (1.52, 2.37)	1.26E- 08	1.57 (0.78, 3.18)	0.207
Waist circumference	1.00 (1.00, 1.01)	0.086	1.01 (1.00, 1.02)	0.133	1.01 (1.00, 1.01)	0.013	1.01 (1.00, 1.03)	0.033	1.00 (0.99, 1.01)	0.747	1.00 (0.98, 1.01)	0.723	1.00 (0.99, 1.01)	0.56	1.00 (0.98, 1.03)	0.93
Hip circumference	1.00 (0.99, 1.00)	0.127	1.00 (0.98, 1.01)	0.793	0.99 (0.99, 1.00)	0.076	1.00 (0.98, 1.02)	0.775	1.00 (0.99, 1.01)	0.962	0.98 (0.96, 1.01)	0.234	1.00 (0.99, 1.01)	0.916	1.00 (0.97, 1.04)	0.821
BMI	1.00 (0.99, 1.01)	0.449	1.01 (0.98, 1.04)	0.375	1.00 (0.99, 1.02)	0.758	1.01 (0.98, 1.05)	0.456	1.01 (0.99, 1.02)	0.486	1.01 (0.97, 1.06)	0.574	1.01 (0.98, 1.03)	0.594	1.01 (0.94, 1.08)	0.844
Currently smoking	1.05 (0.93, 1.18)	0.431	1.22 (0.90, 1.66)	0.201	1.10 (0.94, 1.28)	0.22	1.22 (0.81, 1.83)	0.348	1.00 (0.81, 1.24)	0.993	1.40 (0.88, 2.25)	0.157	0.92 (0.71, 1.21)	0.557	0.39 (0.16, 0.93)	0.033
Exposure to smoking at home	1.00 (0.98, 1.01)	0.513	0.95 (0.85, 1.05)	0.291	0.99 (0.97, 1.01)	0.368	0.94 (0.82, 1.09)	0.424	1.00 (0.99, 1.02)	0.647	0.96 (0.82, 1.11)	0.559	1.00 (0.97, 1.02)	0.879	0.65 (0.29 <i>,</i> 1.45)	0.293
Exposure to smoking out of home	1.00 (0.98, 1.02)	0.908	0.91 (0.79, 1.05)	0.192	1.00 (0.97, 1.03)	0.962	0.89 (0.73, 1.09)	0.276	1.00 (0.97, 1.04)	0.799	0.80 (0.58, 1.10)	0.169	1.01 (0.97, 1.05)	0.671	1.00 (0.87, 1.15)	0.987
	COVID-19:	Coronavirus Dis	sease 2019, MVPA: sel	f-reported m	oderate-to-vigorous phy	ysical activi	ty, AMPA: acceler	ation vector m	agnitude physical a	ctivity, BMI	: body mass index,	OR: odds rat	io, CI: confidence int	erval		

Figure 1 Scatter plots of results from two-sample Mendelian randomisation (MR) analysis

MVPA: moderate-to-vigorous physical activity, COVID-19: coronavirus disease 2019, AMPA: acceleration vector magnitude physical activity, BMI: body mass index.



1 Discussion

2 Our study found that in this UK study population higher AMPA values were inversely associated with 3 overall COVID-19 and outpatient COVID-19 after adjusting for age, sex, measures of obesity in the 4 multivariate model. The association between AMPA and overall COVID-19 persisted after adjusting for smoking status. No association was detected by observational analyses between MVPA or BMI 5 6 and COVID-19. No causal association has been found between any type of PA or BMI and COVID-19 7 outcomes in the MR analysis. 8 Published evidence shows that PA is not only associated with better physical health through 9 pathways such as regulating immunity⁷ but also can benefit mental health.⁸ In addition, for

10 respiratory viral infections, PA can increase the endurance of the respiratory muscles and improve 11 the immune response to respiratory viral antigens.⁹ One review reported that moderate-intensity exercise reduces the risk and severity of respiratory viral infections while vigorous-intensity exercise 12 increases the risk of self-reported respiratory viral infection symptoms.¹⁰ Since there was limited 13 testing capacity at the early stage of the pandemic in the UK, most (76%) of the SARS-CoV-2 testing 14 samples came from hospitalised patients, which can be taken as a surrogate for comparably serious 15 16 disease associated with COVID-19.¹¹ Overall COVID-19 covered confirmed cases from inpatient and outpatient settings, and patients, who died of or with COVID-19. Inpatient COVID-19 indicated 17 18 patients with serious COVID-19 while outpatient COVID-19 indicated patients with relatively milder 19 symptoms. In our analysis, one SD increase of AMPA related to a decreased risk of overall COVID-19 20 and outpatient COVID-19 but not inpatient COVID-19 and COVID-19 death. The effect estimates implied that the objectively measured PA has a larger effect on relatively mild COVID-19 outcomes. 21 22 Since the effect of AMPA was abrogated after adjustment for other covariates highlights the 23 importance of the effect of age, gender, and other co-morbidities for COVID-19 death.

24 This is the first study to analyse the association between PA and COVID-19 quantitatively. One of the 25 advantages of this study is that both objectively and subjectively measured PA were analysed. AMPA 26 is widely considered as a relatively accurate measure of PA, whereas the main advantage of using 27 MVPA is its cost-efficiency. MVPA and AMPA measures were compared in a large Norwegian study 28 and the results indicated that people tend to report less moderate-intensity and more vigorous-29 intensity PA compared to AMPA regardless of gender and age.¹² Older adults also tend to exaggerate 30 the reports of MVPA,¹² perhaps because fragile individuals experience stronger proprioception during exercise. In addition, self-reported questionnaires tend to record more intentional outdoor 31 32 exercise while accelerometers measure all types of exercise.^{13, 14} During the pandemic these 33 differences may intensify. Another advantage of this study was that four COVID-19 outcomes were

analysed. Although more data reflecting serious diseases related to COVID-19 is available, the four
 outcomes can still represent different severity of COVID-19 disease.

3 Our study has several limitations. Firstly, participants of the UKBB tend to be healthier, leaner, and 4 smoke less compared to the general population of the UK, especially for those who accepted the 5 invitation to take part in the accelerometer aspect of the study. Furthermore, UKBB participants 6 were recruited when aged 40 to 69 years old, and so may now have an even higher risk of severe 7 COVID-19 disease. The lower obese/overweight and smoking rate and older age may result in an 8 underestimation of the effects of obesity and smoking status. Secondly, the data for AMPA were 9 obtained between 2013 and 2015, and older age related to a lower AMPA, which could lead to an underestimation of the true effect of AMPA on COVID-19.¹² The data for MVPA and BMI were 10 11 acquired even earlier (2006-2010), so, the historical measures may not be a good proxy for current 12 values. Combining the discrepancy between objectively and subjectively measured PA and the time gap may explain the different results of MVPA and AMPA on COVID-19 related outcomes. Thirdly, 13 14 our study did not support the enhanced effect of BMI on COVID-19, even not for the COVID-19 death outcome.¹⁵ This may be due to the relatively leaner UKBB population, and the time gap between 15 BMI and COVID-19 testing. Finally, testing practices and capacity changed over time in the UK, so the 16 17 earlier data (data prior to 30/05/2020 represent a limited subset of COVID-19 infections. Due to the 18 limited number of test results, the MR analysis had low power to detect a significant association.

19 Conclusion

Our results indicate a protective effect of objectively measured PA and adverse COVID-19 outcomes (outpatient COVID-19 and overall COVID-19) independent of age, sex, measures of obesity, and smoking status. Although the MR analysis did not support a causal association, that may be due to limited power. We conclude that policies to encourage and facilitate exercise at a population level during the pandemic should be considered.

25 Materials and Methods

26 Dataset

The UK-Biobank (UKBB) is a prospective cohort study including more than 500,000 participants aged from 40 to 69 years in the United Kingdom. In this study, participants who have not been tested positive for SARS-CoV-2 and not died of COVID-19 were taken as controls. We removed from the controls the following participants in a sensitivity analysis: i) Those who tested negative, since test results could have been false negative; ii) Participants, who were not from England, since all COVID-19 test results were provided by NHS England only; iii) Participants who died before 01/01/2020. We used both self-reported moderate-to-vigorous PA (MVPA) and acceleration vector magnitude PA

1 (AMPA) as measures of physical activity. MVPA data were mainly acquired during 2006 to 2010 through touch screen questionnaire¹⁶ and AMPA data were collected from a subset of 103,687 UKBB 2 participants wearing an accelerometer for 7 days between 2013 and 2015.¹³ For MVPA, we assigned 3 4 as "NA" for individuals who selected "prefer not to answer" or "do not know" on the questions, 5 individuals reporting being unable to walk, and individuals reporting MPA or VPA for more than 16 6 hours per day. We recoded those reporting >3 hours/day of MPA or VPA to 3 hours. MVPA was 7 calculated by taking the sum of total minutes per week of MPA multiplied by four and the total number of VPA minutes per week multiplied by eight.¹¹ The AMPA covered 103,687 participants in 8 9 UKBB, we removed participants whose data could not be calibrated, values that were unrealistically 10 high (average vector magnitude > 100 mg), or who had poor wear-time. BMI data were collected from 2006 to 2010 and calculated using manual measured weight and height by trained recruiters.¹⁷ 11 12 UKBB released COVID-19 test results with the date of the specimen taken, specimen type (e.g. nasal 13 and throat), the testing laboratory, whether the patient was an inpatient or outpatient when the 14 sample was taken and SARS-CoV-2 testing results. Inpatient samples included inpatient infections,

15 samples taken in emergency departments and health care related infections. From 16/03/2020 to

16 29/06/2020, there were 14,439 SARS-CoV-2 test results among UK Biobank participants with 1,596

17 participants having at least one SARS-CoV-2 positive result and 7,898 participants having one or

18 more negative results. Of these individuals, 7,187 were inpatients and 2,307 were outpatients. We

19 analysed four COVID-19 related outcomes: overall COVID-19, included all patients (inpatients,

20 outpatients or deaths); inpatient COVID-19, included all inpatients with at least one positive SARS-

21 CoV-2 testing result; outpatient COVID-19, included outpatients who tested SARS-CoV-2 positive at

22 least once; COVID-19 death, included death caused by clinical and epidemiological diagnosed COVID-

23 19 (both primary and contributory causes of death).

24 Subsequently, we performed two-sample MR analysis to test the causality between PA and BMI and

25 COVID-19 in UKBB. The detailed description of genotyping, quality control and genetic imputation

26 have been described previously.¹⁸ From a total of 488,366 participants in the UKBB with genotype

27 data, 149,110 samples were excluded due to consent withdrawals, non-white British ethnic

28 background, sex mismatch, sex aneuploidy, high missing rate/outlier, and kinship inference. The

29 genetic instruments for MVPA, AMPA, and BMI were extracted from the largest available GWAS

30 datasets.¹⁹⁻²¹ Seven, five, and 68 common genetic variants were extracted for MVPA, AMPA, and BMI

31 respectively after considering linkage disequilibrium (LD) (r^2 >0.2).

1 Statistical analyses

- 2 To describe the characteristics of participants, mean and standard deviation (SD) are presented for
- 3 continuous covariates, and number (N) and percentage (%) are presented for categorical covariates.
- 4 We performed both univariate and multivariate logistic regression analysis to test the association
- 5 between two measures of PA and four COVID-19 related outcomes. In the multivariate logistic
- 6 regression model, we first added age and sex as covariates, then we further added measures of
- 7 obesity or overweight (waist circumference, hip circumference, and BMI), and finally, we added
- 8 smoking measures (current smoking status, exposure to smoking at home and exposure to smoking
- 9 out of home). The details of the covariates can be found in Bycroft et al.¹⁷
- 10 For the MR analysis, we tested the association between genetic instruments of the exposures and
- 11 COVID-19 by performing multivariate logistic regression adjusting for age, sex, the first 10 principal
- 12 components (PCs), and the assessment centre in UKBB. The causal effects and the corresponding
- 13 standard errors of exposures on the outcome were calculated by using a random effect inverse-variant
- 14 weighted (IVW) method.²² We evaluated the heterogeneity among the causal effects of each variant
- 15 (Cochran's Q statistic) and a P-value lower than 0.10²³ was regarded as statistically significant
- 16 heterogeneity. We performed MR-Egger²⁴ as a sensitivity analysis to explore the potential bias
- 17 introduced by horizontal pleiotropy.
- The P-value threshold was set at 0.05 for all the analyses. All statistical analyses were performed on R
 v3.6.1.

20 Competing interests

21 The authors declare that they have no conflict of interest.

22 Funding

- 23 This work was supported by Cancer Research UK programme grant to MD [grant number
- 24 C348/A18927]; Cancer Research UK Career Development Fellowship to ET [grant number
- 25 C31250/A22804]; The Darwin Trust of Edinburgh studentship to XZ.

26 Acknowledgments

- 27 We would like to express our gratitude to the support from Edinburgh CRUK Cancer Research Centre
- as well as support from all trustees of the Darwin Trust of Edinburgh. This research has been
- 29 conducted using the UK Biobank Resource under Application Number 10775.

Reference

1 World Health Organization. Coronavirus disease (COVID-2019) situation reports 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200729-covid-19-sitrep-191.pdf?sfvrsn=2c327e9e 2. [29/07] [2020]

Lesser IA, Nienhuis CP. The Impact of COVID-19 on Physical Activity Behavior and Well-Being 2 of Canadians. Int J Environ Res Public Health. 2020;17(11).

https://www.ncbi.nlm.nih.gov/pubmed/32486380.

3 Rezende LFM, Sa TH, Markozannes G, et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. Br J Sports Med. 2018;52(13):826-33. https://www.ncbi.nlm.nih.gov/pubmed/29146752.

Vasankari V, Husu P, Vaha-Ypya H, et al. Association of objectively measured sedentary 4 behaviour and physical activity with cardiovascular disease risk. Eur J Prev Cardiol. 2017;24(12):1311-8. https://www.ncbi.nlm.nih.gov/pubmed/28530126.

Sellami M, Gasmi M, Denham J, et al. Effects of Acute and Chronic Exercise on 5 Immunological Parameters in the Elderly Aged: Can Physical Activity Counteract the Effects of Aging? Front Immunol. 2018;9:2187. https://www.ncbi.nlm.nih.gov/pubmed/30364079.

Carter SJ, Baranauskas MN, Fly AD. Considerations for Obesity, Vitamin D, and Physical 6 Activity Amid the COVID-19 Pandemic. Obesity (Silver Spring, Md). 2020;28(7):1176-7. https://www.ncbi.nlm.nih.gov/pubmed/32299148.

7 Simpson RJ, Kunz H, Agha N, et al. Exercise and the Regulation of Immune Functions. Prog Mol Biol Transl Sci. 2015;135:355-80. https://www.ncbi.nlm.nih.gov/pubmed/26477922.

White RL, Babic MJ, Parker PD, et al. Domain-Specific Physical Activity and Mental Health: A 8 Meta-analysis. Am J Prev Med. 2017;52(5):653-66.

https://www.ncbi.nlm.nih.gov/pubmed/28153647.

Jakobsson J, Malm C, Furberg M, et al. Physical Activity During the Coronavirus (COVID-19) 9 Pandemic: Prevention of a Decline in Metabolic and Immunological Functions. Front sports act living. 2020;2(57). https://www.frontiersin.org/article/10.3389/fspor.2020.00057.

10 Martin SA, Pence BD, Woods JA. Exercise and respiratory tract viral infections. Exerc Sport Sci *Rev.* 2009;37(4):157-64. https://www.ncbi.nlm.nih.gov/pubmed/19955864.

Biobank U. Records of COVID-19 test results 2020 [Available from: 11

http://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=40100. [25/06] [2020]

Dyrstad SM, Hansen BH, Holme IM, et al. Comparison of self-reported versus accelerometer-12 measured physical activity. *Med Sci Sports Exerc*. 2014;46(1):99-106. https://www.ncbi.nlm.nih.gov/pubmed/23793232.

Doherty A, Jackson D, Hammerla N, et al. Large Scale Population Assessment of Physical 13

Activity Using Wrist Worn Accelerometers: The UK Biobank Study. PLoS One. 2017;12(2):e0169649. https://www.ncbi.nlm.nih.gov/pubmed/28146576.

14 Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-95. https://www.ncbi.nlm.nih.gov/pubmed/12900694.

Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are 15 independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism: clinical and experimental. 2020;108:154262. https://www.ncbi.nlm.nih.gov/pubmed/32422233.

Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the 16 causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. https://www.ncbi.nlm.nih.gov/pubmed/25826379.

17 Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9. https://www.ncbi.nlm.nih.gov/pubmed/30305743.

18 Meng X, Li X, Timofeeva MN, et al. Phenome-wide Mendelian-randomization study of genetically determined vitamin D on multiple health outcomes using the UK Biobank study. Int J Epidemiol. 2019;48(5):1425-34. https://www.ncbi.nlm.nih.gov/pubmed/31518429.

Klimentidis YC, Raichlen DA, Bea J, et al. Genome-wide association study of habitual physical 19 activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond). 2018;42(6):1161-76. https://www.ncbi.nlm.nih.gov/pubmed/29899525.

Doherty A, Smith-Byrne K, Ferreira T, et al. GWAS identifies 14 loci for device-measured 20 physical activity and sleep duration. Nat Commun. 2018;9(1):5257. https://www.ncbi.nlm.nih.gov/pubmed/30531941.

Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for 21 obesity biology. Nature. 2015;518(7538):197-206.

https://www.ncbi.nlm.nih.gov/pubmed/25673413.

Burgess S, Scott RA, Timpson NJ, et al. Using published data in Mendelian randomization: a 22 blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543-52. https://www.ncbi.nlm.nih.gov/pubmed/25773750.

Higgins J, Green S. Chapter 9: Analysing data and undertaking meta-analyses. In: Jonathan J, 23 Higgins J, Douglas G, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Mar. p. 28.

24 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25. https://www.ncbi.nlm.nih.gov/pubmed/26050253.

Table S1 Association analysis between obesity measures and four COVID-19 related outcomes											
	Overall COV	ID-19		Inpatient COV	/ID-19		Outpatient CO	VID-19		COVID-19 E	Death
	OR (95%CI)	Р		OR (95%CI)	Р		OR (95%CI)	Р		OR (95%CI)	Р
BMI	1.02 (0.98, 1.07)	0.317		1.01 (0.95, 1.07)	0.729		1.05 (0.97, 1.14)	0.218		1.04 (0.94, 1.14)	0.461
BMI	1.02 (0.98, 1.07)	0.324		1.01 (0.95, 1.07)	0.743		1.05 (0.97, 1.14)	0.217		1.04 (0.94, 1.14)	0.478
Age	1.00 (1.00, 1.01)	0.154		1.02 (1.01, 1.02)	4.26E-04		0.96 (0.95, 0.97)	3.81E-13		1.13 (1.11, 1.15)	2.52E-45
Sex	1.34 (1.22, 1.47)	1.01E-09		1.51 (1.33, 1.70)	1.04E-10		1.03 (0.87, 1.21)	0.767		1.99 (1.62, 2.44)	4.73E-11
BMI	1.02 (0.98, 1.07)	0.316		1.01 (0.95, 1.08)	0.673		1.05 (0.97, 1.13)	0.262		1.03 (0.94, 1.14)	0.506
Age	1.00 (1.00, 1.01)	0.156		1.02 (1.01, 1.02)	4.24E-04		0.96 (0.95, 0.97)	2.54E-13		1.13 (1.11, 1.15)	3.36E-45
Sex	1.34(1.21, 1.47)	2.27E-09		1.50 (1.32, 1.70)	1.66E-10		1.01 (0.86, 1.19)	0.883		1.98 (1.61, 2.43)	6.79E-11
Waist circumference (cm)	1.00 (1.00, 1.01)	0.231		1.00 (1.00, 1.01)	0.05		1.00 (0.99, 1.01)	0.789		1.00 (0.99, 1.01)	0.78
Hip circumference (cm)	1.00 (0.99, 1.00)	0.166		0.99 (0.99, 1.00)	0.1		1.00 (0.99, 1.01)	0.992		1.00 (0.99, 1.01)	0.651
BMI	1.02 (0.97, 1.07)	0.45		1.01 (0.95, 1.08)	0.761		1.03 (0.95, 1.13)	0.483		1.03 (0.93, 1.14)	0.594
Age	1.00 (1.00, 1.01)	0.144		1.02 (1.01, 1.02)	4.35E-04		0.96 (0.95, 0.97)	2.39E-12		1.13 (1.11, 1.16)	4.46E-40
Sex	1.36 (1.22, 1.50)	5.91E-09		1.51 (1.32, 1.72)	2.91E-09		1.08 (0.91, 1.30)	0.375		1.90 (1.52, 2.37)	1.26E-08
Waist circumference (cm)	1.00 (1.00, 1.01)	0.086		1.01 (1.00, 1.01)	0.013		1.00 (0.99, 1.01)	0.747		1.00 (0.99, 1.01)	0.56
Hip circumference (cm)	1.00 (0.99, 1.00)	0.127		0.99 (0.99, 1.00)	0.076		1.00 (0.99, 1.01)	0.963		1.00 (0.99, 1.01)	0.916
Currently Smoking	1.05 (0.93, 1.18)	0.431		1.10 (0.94, 1.28)	0.22		1.00 (0.81, 1.24)	0.994		0.92 (0.71, 1.21)	0.557
Exposure to smoking at home (hour/week)	1.00 (0.98, 1.01)	0.513		0.99 (0.97, 1.01)	0.37		1.00 (0.99, 1.02)	0.648		1.00 (0.97, 1.02)	0.879
Exposure to smoking out of home (hour/week)	1.00 (0.98, 1.02)	0.908		1.00 (0.97, 1.03)	0.962		1.00 (0.97, 1.04)	0.798		1.01 (0.97, 1.05)	0.671
CC	VID-19: Coronavirus	s Disease 202	L9,	BMI: body mass inde	ex, OR: odds	rati	o, CI: confidence inte	erval			

Tabl	Table S2 Results of two-sample Mendelian randomisation studies between physical activity exposures or BMI and COVID-19 outcomes												
	MVPA	AMPA BMI											
	OR (95%CI)	Р	Pint	Phet	OR (95%CI)	Р	Pint	Phet	OR (95%CI)	Р	Pint	Phet	
IVW	0.37 (0.03, 5.08)	0.46	/	0.28	1.36 (0.20,9.21)	0.76	/	0.13	1.37 (0.90,2.09)	0.14	/	0.31	
MR-Egger	0.01 (8.58E-8, 1061.38)	0.43	0.53	/	8.42E-7 (4.56E-12,0.16)	0.02	0.02	/	1.15 (0.41,3.20)	0.79	0.71	/	
COVID-19: Coronavirus Disease 201	19, MVPA: self-reported moderate-t	o-vigoro	us phys	ical activ	vity, AMPA: acceleration vector mag	nitude pł	nysical ad	ctivity, B	MI: body mass inde	x, OR: o	dds rat	io, CI:	
	cor	nfidence	interva	l, IVW: i	nverse variance weighted method								

Table S3 Sensitivity ana	lysis for the asso	ociation be	etween physical a	activity me	asures and four CO	VID-19 rel	ated outcomes af CoV-2	ter excludi	ng controls not fro	m England	d, that died befo	re 01/01/20	20, and participar	its that tes	ted negative for	r SARS-
		Overall (COVID-19			Inpatient	COVID-19			Outpatien	t-COVID-19			COVID-1	9 death	
	MVPA (Subje measure	ectively ed)	AMPA (Obje measure	ctively ed)	MVPA (Subje measure	ectively ed)	AMPA (Objec measured	tively d)	MVPA (Subj measure	ectively ed)	AMPA (Obje measure	ectively ed)	MVPA (Subje measure	ectively ed)	AMPA (Obje measure	ectively ed)
	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р
Physical activity	1.01 (0.97, 1.06)	0.603	0.83 (0.72, 0.96)	0.012	1.05 (0.99, 1.11)	0.108	0.82 (0.67, 0.99)	0.039	0.94 (0.86, 1.02)	0.151	0.91 (0.72, 1.15)	0.423	1.03 (0.94, 1.14)	0.501	0.54 (0.36, 0.81)	0.003
Physical activity	1.01 (0.97, 1.06)	0.606	0.79 (0.68, 0.91)	0.002	1.05 (0.99, 1.11)	0.108	0.83 (0.68, 1.01)	0.065	0.94 (0.86, 1.02)	0.149	0.74 (0.58, 0.94)	0.014	1.03 (0.94, 1.14)	0.497	0.76 (0.51, 1.15)	0.191
Age	1.00 (1.00, 1.02)	0.002	0.97 (0.95, 0.99)	5.42E- 04	1.02 (1.01, 1.03)	8.97E- 07	1.00 (0.97, 1.02)	0.85	0.97 (0.96, 0.98)	1.55E- 10	0.90 (0.88, 0.93)	2.26E- 11	1.14 (1.12, 1.16)	4.32E- 50	1.18 (1.10, 1.27)	1.75E- 06
Sex	1.39 (1.27, 1.53)	5.87E- 12	1.38 (1.06, 1.81)	0.019	1.57 (1.38, 1.77)	1.29E- 12	1.85 (1.29, 2.66)	0.001	1.05 (0.89, 1.24)	0.535	0.85 (0.54, 1.34)	0.487	2.12 (1.73, 2.60)	5.86E- 13	1.90 (0.96, 3.76)	0.067
Physical activity	1.02 (0.97, 1.06)	0.515	0.79 (0.68, 0.92)	0.002	1.05 (0.99, 1.11)	0.11	0.83 (0.68, 1.02)	0.073	0.95 (0.87, 1.03)	0.23	0.74 (0.58, 0.95)	0.017	1.04 (0.94, 1.14)	0.46	0.76 (0.51, 1.14)	0.189
Age	1.01 (1.00, 1.02)	0.002	0.97 (0.95, 0.99)	4.68E- 04	1.02 (1.01, 1.03)	1.10E- 06	1.00 (0.97, 1.02)	0.852	0.97 (0.96, 0.98)	1.34E- 10	0.90 (0.87, 0.93)	1.18E- 11	1.14 (1.12, 1.16)	4.31E- 50	1.18 (1.10, 1.27)	1.78E- 06
Sex	1.39 (1.26, 1.52)	1.52E- 11	1.35 (1.03, 1.77)	0.03	1.56 (1.38, 1.77)	2.51E- 12	1.82 (1.27, 2.62)	0.001	1.04 (0.88, 1.23)	0.625	0.81 (0.51, 1.29)	0.37	2.10 (1.71, 2.58)	1.30E- 12	1.89 (0.95, 3.75)	0.068
Waist circumference	1.00 (1.00, 1.01)	0.221	1.00 (0.99, 1.01)	0.571	1.00 (1.00, 1.01)	0.048	1.01 (1.00, 1.03)	0.054	1.00 (0.99, 1.01)	0.813	0.99 (0.97, 1.00)	0.099	1.00 (0.99, 1.01)	0.797	1.00 (0.98, 1.03)	0.902
Hip circumference	1.00 (0.99, 1.00)	0.179	1.00 (0.99, 1.02)	0.856	0.99 (0.99, 1.00)	0.107	1.01 (0.98, 1.02)	0.863	1.00 (0.99, 1.01)	0.992	1.00 (0.97, 1.02)	0.904	1.00 (0.99, 1.01)	0.692	0.99 (0.95, 1.03)	0.66
ВМІ	1.01 (1.00, 1.01)	0.308	1.01 (0.98, 1.04)	0.532	1.00 (0.99, 1.02)	0.665	1.00 (0.96, 1.04)	0.96	1.01 (0.99, 1.03)	0.258	1.03 (0.98, 1.07)	0.209	1.01 (0.99, 1.03)	0.511	0.99 (0.92, 1.06)	0.744
Physical activity	1.00 (0.95, 1.06)	0.904	0.81 (0.68, 0.95)	0.009	1.05 (0.98, 1.11)	0.175	0.84 (0.67, 1.04)	0.102	0.93 (0.85, 1.03)	0.151	0.79 (0.60, 1.02)	0.072	1.00 (0.90, 1.11)	0.995	0.72 (0.46, 1.11)	0.135
Age	1.00 (1.00, 1.02)	0.002	0.98 (0.96, 1.00)	0.015	1.02 (1.01, 1.03)	2.09E- 06	1.01 (0.98, 1.03)	0.568	0.97 (0.96, 0.98)	6.22E- 10	0.90 (0.87, 0.93)	1.32E- 09	1.14 (1.12, 1.17)	3.24E- 44	1.21 (1.12, 1.31)	9.50E- 07
Sex	1.41 (1.27, 1.56)	6.67E- 11	1.42 (1.06, 1.90)	0.017	1.56 (1.37, 1.79)	8.10E- 11	1.97 (1.33, 2.92)	0.001	1.12 (0.93, 1.33)	0.227	0.85 (0.52, 1.40)	0.52	2.01 (1.62, 2.51)	4.92E- 10	1.62 (0.80, 3.27)	0.18
Waist circumference	1.00 (1.00, 1.01)	0.084	1.01 (1.00, 1.02)	0.143	1.01 (1.00, 1.01)	0.013	1.01 (1.00, 1.03)	0.037	1.00 (0.99, 1.01)	0.757	1.00 (0.98, 1.02)	0.731	1.00 (0.99, 1.01)	0.573	1.00 (0.98, 1.03)	0.944
Hip circumference	1.00 (0.99, 1.00)	0.143	1.00 (0.98, 1.01)	0.797	0.99 (0.99, 1.00)	0.083	1.00 (0.98, 1.02)	0.777	1.00 (0.99, 1.01)	0.936	0.98 (0.96, 1.01)	0.242	1.00 (0.99, 1.01)	0.977	1.00 (0.97, 1.04)	0.809

								1					1					
BMI	1.00 (0.99, 0.445 1.01 (0.98, 0.384 1.00 (0.99, 0.758		1.01 (0.98,	0 473		1.01 (0.99,	0 478	1.01 (0.97,	0 565		1.01 (0.98,	0 608	1.01 (0.94,	0 877				
BIVII	1.01)	0.445	1.04)	0.364	1.02)	0.758	1.05)	0.475		1.03)	0.478	1.07)	0.505		1.03)	0.008	1.08)	0.877
Currently, and line	1.05 (0.93,	0 411	1.24 (0.91,	0.170	1.10 (0.95,	0.200	1.23 (0.82,	0.210		1.00 (0.81,	0.000	1.41 (0.88,	0.1.40		0.93 (0.71,	0.574	0.40 (0.17,	0.020
Currently smoking	1.18)	0.411	1.68)	0.178	1.28)	0.209	1.85)	0.319		1.24)	0.993	2.26)	0.149		1.21)	0.574	0.95)	0.038
Exposure to smoking at	1.00 (0.98,	0.505	0.95 (0.85,	0.000	0.99 (0.97,	0.000	0.95 (0.83,	0.422		1.00 (0.99,	0.00	0.96 (0.83,	0.560		1.00 (0.97,	0.070	0.64 (0.28,	0.000
home	1.01)	0.505	1.05)	0.299	1.01)	0.366	1.09)	0.432		1.02)	0.66	1.11)	0.563		1.02)	0.878	1.46)	0.289
Exposure to smoking	1.00 (0.98,	0.020	0.91 (0.79,	0 202	1.00 (0.97,	0.070	0.90 (0.73,	0.207		1.00 (0.97,	0 702	0.80 (0.57,	0 174		1.01 (0.97,	0.050	1.00 (0.87,	0.074
out of home	1.02)	0.928	1.05)	0.203	1.03)	0.979	1.10)	0.287		1.04)	0.793	1.11)	0.174		1.05)	0.656	1.15)	0.974
COVID-19:	Coronavirus Dise	ase 2019	, MVPA: self-rep	orted mod	lerate-to-vigorous p	hysical ac	tivity, AMPA: acce	leration v	ecto	or magnitude ph	ysical acti	vity, BMI: body	mass inde	x, OR:	odds ratio, CI:	confidenc	e interval	

Table S4 Association analysis between BMI and	Table S4 Association analysis between BMI and four COVID-19 related outcomes after excluding controls not from England, that died before 01/01/2020, and participants that tested negative for SARS-CoV-2													
	COVID-19			Inpatient COVI	D-19		Outpatient COV	/ID-19		COVID-19 Death				
	OR (95%CI)	Р		OR (95%CI)	Р		OR (95%CI)	Р		OR (95%CI)	Р			
BMI	1.02 (0.98, 1.07)	0.301		1.01 (0.95, 1.08)	0.71		1.05 (0.97, 1.14)	0.21		1.04 (0.94, 1.14)	0.451			
BMI	1.02 (0.98, 1.07)	0.315		1.01 (0.95, 1.07)	0.736		1.05 (0.97, 1.14)	0.209		1.04 (0.94, 1.14)	0.482			
Age	1.01 (1.00, 1.02)	0.002		1.02 (1.01, 1.03)	1.08E-06		0.97 (0.96, 0.98)	2.02E-10		1.14 (1.12, 1.16)	3.14E-50			
Sex	1.39 (1.27, 1.53)	5.69E-12		1.57 (1.38, 1.77)	1.36E-12		1.06 (0.90, 1.24)	5.22E-01		2.11 (1.72, 2.59)	8.56E-13			
BMI	1.02 (0.98, 1.07)	0.309		1.01 (0.95, 1.08)	0.669		1.05 (0.97, 1.14)	0.256		1.03 (0.94, 1.14)	0.511			
Age	1.01 (1.00, 1.02)	0.002		1.02 (1.01, 1.03)	1.11E-06		0.97 (0.96, 0.98)	1.35E-10		1.14 (1.12, 1.16)	4.36E-50			
Sex	1.39 (1.26, 1.52)	1.52E-11		1.56 (1.38, 1.77)	2.49E-12		1.04 (0.88, 1.23)	6.25E-01		2.10 (1.71, 2.58)	1.29E-12			
Waist circumference (cm)	1.00 (1.00, 1.01)	0.221		1.00 (1.00, 1.01)	0.048		1.00 (0.99, 1.01)	0.813		1.00 (0.99, 1.01)	0.798			
Hip circumference (cm)	1.00 (0.99, 1.00)	0.179		0.99 (0.99, 1.00)	0.107		1.00 (0.99, 1.01)	0.992		1.00 (0.99, 1.01)	0.692			
BMI	1.02 (0.97, 1.07)	0.445		1.01 (0.94, 1.08)	0.762		1.03 (0.95, 1.13)	0.474		1.03 (0.92, 1.14)	6.08E-01			
Age	1.01 (1.00, 1.02)	0.002		1.02 (1.01, 1.03)	2.10E-06		0.97 (0.96, 0.98)	6.23E-10		1.14 (1.12, 1.17)	3.24E-44			
Sex	1.41 (1.27, 1.56)	6.66E-11		1.57 (1.37, 1.79)	2.10E-06		1.12 (0.93, 1.33)	0.228		2.01 (1.62, 2.51)	4.923E-10			
Waist circumference (cm)	1.00 (1.00, 1.01)	0.084		1.01 (1.00, 1.01)	0.013		1.00 (0.99, 1.01)	0.758		1.00 (0.99, 1.01)	0.573			
Hip circumference (cm)	1.00 (0.99, 1.00)	0.143		0.99 (0.99, 1.00)	0.083		1.00 (0.99, 1.01)	0.937		1.00 (0.99, 1.01)	0.977			
Currently Smoking	1.05 (0.93, 1.18)	0.411		1.10 (0.95, 1.28)	0.21		1.00 (0.81, 1.24)	0.992		0.93 (0.71, 1.21)	0.574			
Exposure to smoking at home (hour/week)	1.00 (0.98, 1.01)	0.505		0.99 (0.97, 1.01)	0.366		1.00 (0.99, 1.02)	0.659		1.00 (0.97, 1.02)	0.878			
Exposure to smoking out of home (hour/week)	1.00 (0.98, 1.02)	0.928		1.00 (0.97, 1.03)	0.979		1.00 (0.97, 1.04)	0.79157		1.01 (0.97, 1.05)	0.656			
	COVID-19: Coror	avirus Disease	20	19, BMI: body mass inde	ex, OR: odds ra	atio	, CI: confidence interval							

Table	S5 Effect estim	ates of each instr	rumenta	al varia	ble of ead	ch exposure	(MVPA, A	MPA, BMI) on	the overall	COVID-19 outcon	ne
SNP	Exposure	BP	CHR	EA	EAF	Beta.PA	SE.PA	Beta.BMI	SE.BMI	Beta.COVID	SE.COVID
rs149943	MVPA	28002388	6	G/A	0.85	0.019	0.005	/	/	-0.067	0.059
rs2035562	MVPA	85056521	3	A/G	0.33	-0.014	0.004	/	/	-0.021	0.046
rs2854277	MVPA	32628084	6	C/T	0.92	0.031	0.008	/	/	-0.079	0.097
rs2988004	MVPA	37044388	9	T/G	0.56	-0.013	0.003	/	/	0.036	0.044
rs3094622	MVPA	30327952	6	A/G	0.86	0.02	0.005	/	/	0.009	0.063
rs7791992	MVPA	50237784	7	C/A	0.41	-0.014	0.003	/	/	-0.075	0.044
rs7804463	MVPA	133447651	7	T/C	0.53	0.015	0.003	/	/	-0.068	0.043
rs59499656	AMPA	40768309	18	A/T	0.655	-0.028	0.005	/	/	-0.062	0.045
rs6895232	AMPA	152039421	5	T/A	0.663	0.027	0.005	/	/	0.009	0.046
rs564819152	AMPA	21820650	10	A/G	0.679	0.028	0.005	/	/	0.056	0.047
rs55657917	AMPA	44326864	17	A/G	0.77	-0.037	0.005	/	/	0.106	0.054
rs6775319	AMPA	18758501	3	A/T	0.271	0.027	0.005	/	/	0.02	0.049
rs1000940	BMI	5283252	17	G/A	0.32	/	/	0.019	0.003	-0.009	0.047
rs10938397	BMI	45182527	4	G/A	0.434	/	/	0.04	0.003	-0.097	0.044
rs10968576	BMI	28414339	9	G/A	0.32	/	/	0.025	0.003	0.053	0.046
rs11126666	BMI	26928811	2	A/G	0.283	/	/	0.021	0.003	-0.003	0.05
rs11165643	BMI	96924097	1	T/C	0.583	/	/	0.022	0.003	-0.015	0.044
rs11191560	BMI	104869038	10	C/T	0.089	/	/	0.031	0.005	0.091	0.078
rs1167827	BMI	75163169	7	G/A	0.553	/	/	0.02	0.003	-0.009	0.044
rs11847697	BMI	30515112	14	T/C	0.042	/	/	0.049	0.008	-0.033	0.108
rs12286929	BMI	115022404	11	G/A	0.523	/	/	0.022	0.003	0.045	0.043
rs12401738	BMI	78446761	1	A/G	0.352	/	/	0.021	0.003	0.067	0.044
rs12429545	BMI	54102206	13	A/G	0.133	/	/	0.033	0.05	0.04	0.064
rs13021737	BMI	632348	2	G/A	0.828	/	/	0.06	0.004	-0.037	0.057
rs13107325	BMI	103188709	4	T/C	0.072	/	/	0.048	0.007	-0.009	0.083
rs1516725	BMI	185824004	3	C/T	0.872	/	/	0.045	0.005	0.004	0.063
rs1528435	BMI	181550962	2	T/C	0.631	/	/	0.018	0.003	0.049	0.045
rs1558902	BMI	53803574	16	A/T	0.415	/	/	0.082	0.003	0.065	0.044
rs16851483	BMI	141275436	3	T/G	0.066	/	/	0.048	0.008	-0.046	0.089
rs17001654	BMI	77129568	4	G/C	0.153	/	/	0.031	0.005	-0.04	0.063
rs17024393	BMI	110154688	1	C/T	0.04	/	/	0.066	0.009	0.105	0.13
rs17094222	BMI	102395440	10	C/T	0.211	/	/	0.025	0.004	0.059	0.052
rs2033529	BMI	40348653	6	G/A	0.293	/	/	0.019	0.003	0.068	0.047
rs2033732	BMI	85079709	8	C/T	0.747	/	/	0.019	0.004	-0.06	0.049
rs205262	BMI	34563164	6	G/A	0.273	/	/	0.022	0.004	0.016	0.049
rs2121279	BMI	143043285	2	T/C	0.152	/	/	0.025	0.004	0.059	0.064
rs2207139	BMI	50845490	6	G/A	0.177	/	/	0.045	0.004	-0.01	0.058
rs29941	BMI	34309532	19	G/A	0.669	/	/	0.018	0.003	0.008	0.046
rs3101336	BMI	72751185	1	C/T	0.613	/	/	0.033	0.003	-0.023	0.044
rs3810291	BMI	47569003	19	A/G	0.666	/	/	0.028	0.004	0.01	0.046
rs3817334	BMI	47650993	11	T/C	0.407	/	/	0.026	0.003	0.049	0.044
rs3849570	BMI	81792112	3	A/C	0.359	/	/	0.019	0.003	0.013	0.045

rs3888190	BMI	28889486	16	A/C	0.403	/	/	0.031	0.003	0.03	0.044		
rs4256980	BMI	8673939	11	G/C	0.646	/	/	0.021	0.003	-0.088	0.045		
rs543874	BMI	177889480	1	G/A	0.193	/	/	0.048	0.004	0.042	0.053		
rs6567160	BMI	57829135	18	C/T	0.236	/	/	0.056	0.004	-0.036	0.052		
rs6804842	BMI	25106437	3	G/A	0.575	/	/	0.019	0.003	-0.033	0.044		
rs7138803	BMI	50247468	12	A/G	0.384	/	/	0.032	0.003	0.079	0.044		
rs7141420	BMI	79899454	14	T/C	0.527	/	/	0.024	0.003	0.015	0.044		
rs758747	BMI	3627358	16	T/C	0.265	/	/	0.023	0.004	-0.015	0.049		
rs7899106	BMI	87410904	10	G/A	0.052	/	/	0.04	0.007	-0.01	0.099		
rs9400239	BMI	108977663	6	C/T	0.688	/	/	0.019	0.003	0.019	0.048		
rs10132280	BMI	25928179	14	C/A	0.682	/	/	0.023	0.003	-0.016	0.047		
rs1016287	BMI	59305625	2	T/C	0.287	/	/	0.023	0.003	-0.08	0.048		
rs10733682	BMI	129460914	9	A/G	0.478	/	/	0.017	0.003	-0.018	0.044		
rs11030104	BMI	27684517	11	A/G	0.792	/	/	0.041	0.004	0.083	0.055		
rs11057405	BMI	122781897	12	G/A	0.901	/	/	0.031	0.006	-0.065	0.069		
rs11688816	BMI	63053048	2	G/A	0.525	/	/	0.017	0.003	-0.014	0.044		
rs1218793	BMI	28007830	13	T/C	0.203	/	/	0.03	0.005	-0.038	0.046		
rs12446632	BMI	19935389	16	G/A	0.865	/	/	0.04	0.005	0.041	0.063		
rs12566985	BMI	75002193	1	G/A	0.446	/	/	0.024	0.003	0.03	0.044		
rs12940622	BMI	78615571	17	G/A	0.575	/	/	0.018	0.003	-0.026	0.043		
rs13191362	BMI	163033350	6	A/G	0.879	/	/	0.028	0.005	0.054	0.067		
rs17405819	BMI	76806584	8	T/C	0.7	/	/	0.022	0.003	-0.103	0.046		
rs17724992	BMI	18454825	19	A/G	0.746	/	/	0.019	0.004	0.007	0.049		
rs1808579	BMI	21104888	18	C/T	0.534	/	/	0.017	0.003	0.105	0.043		
rs1928295	BMI	120378483	9	T/C	0.548	/	/	0.019	0.003	0.029	0.044		
rs2112347	BMI	75015242	5	T/G	0.629	/	/	0.026	0.003	-0.112	0.045		
rs2176598	BMI	43864278	11	T/C	0.251	/	/	0.02	0.004	-0.041	0.051		
rs2245368	BMI	76608143	7	C/T	0.18	/	/	0.032	0.006	0.071	0.056		
rs2287019	BMI	46202172	19	C/T	0.804	/	/	0.036	0.004	0.05	0.057		
rs2365389	BMI	61236462	3	C/T	0.582	/	/	0.02	0.003	0.07	0.044		
rs3736485	BMI	51748610	15	A/G	0.454	/	/	0.018	0.003	0.023	0.044		
rs4740619	BMI	15634326	9	T/C	0.542	/	/	0.018	0.003	0.046	0.044		
rs6477694	BMI	111932342	9	C/T	0.365	/	/	0.017	0.003	-0.003	0.045		
rs657452	BMI	49589847	1	A/G	0.394	/	/	0.023	0.003	0.073	0.044		
rs7243357	BMI	56883319	18	T/G	0.812	/	/	0.022	0.004	0.121	0.059		
rs7599312	BMI	213413231	2	G/A	0.724	/	/	0.022	0.003	-0.024	0.049		
rs7903146	BMI	114758349	10	C/T	0.713	/	/	0.023	0.003	0.021	0.048		
rs9925964	BMI	31129895	16	A/G	0.62	/	/	0.019	0.003	0.021	0.045		
SNP: single-nu	SNP: single-nucleotide polymorphism, EA: effect allele, EAF: effect allele frequency, PA: physical activity, SE: standard error, COVID: Coronavirus												
Disease 2019, N	1VPA: self-repo	orted moderate-t	o-vigor	ous phy	sical acti	vity, AMPA:	accelerati	on vector mag	gnitude phys	sical activity, BMI	: body mass		
			-			index		-		-			